Exagen Inc. (XGN) stock
XGNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3010% above fair value
$3.76−0.01 (-0.27%)
Close on Nov 17, 2026Market cap $91.09MP/E –Yield –
Exagen price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Exagen's price to book ratio was 10.0× on Nov 11, 2026, against 9.8× a year earlier. Over the last 5 years it ranged from 0.6× to 23.5×, with a median of 1.7×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 10.0× | +2.4 |
| 2025 | Dec 31, 2025 | 7.5× | +2.0 |
| 2024 | Dec 31, 2024 | 5.6× | +4.4 |
| 2023 | Dec 29, 2023 | 1.2× | +0.5 |
| 2022 | Dec 30, 2022 | 0.7× | −1.4 |
| 2021 | Dec 31, 2021 | 2.1× | −1.7 |
| 2020 | Dec 31, 2020 | 3.8× | −1.7 |
| 2019 | Dec 31, 2019 | 5.4× | – |
See a number that looks wrong?